Trial Profile

B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Rituximab
Indications Renal transplant rejection
Focus Adverse reactions

Most Recent Events

29 Jun 2020 Planned End Date changed from 1 Sep 2019 to 1 Sep 2021.
29 Jun 2020 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2021.
24 Sep 2019 Results assessing safety, toxicity and preliminary efficacy of carfilzomib in highly HLA- sensitized kidney transplant candidates published in the American Journal of Transplantation

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com